The SPERA™ COVID-19 Antigen Test is an easy to use, high quality rapid SARS-CoV-2 antigen test with an industry leading sensitivity rate of 92% and specificity rate of 97%. FDA authorized at the point-of-care, the SPERA™ COVID-19 Ag tests is specifically designed for high volume and efficient testing to support a safer return to schools, travel and workplaces.

Made in Japan. Best-in-class Japanese manufacturing, the SPERA™ COVID-19 Antigen Test is a premium and highly effective test, verified to be effective against major circulating variants including the Delta variant as well as the Alpha, Beta and Gamma.

Fast, Reliable, Effective and Affordable. The SPERA™ COVID-19 Antigen Test is an optimal testing solution for healthcare professionals who value high quality testing in outpatient clinical centers. Multiple SPERA™ COVID-19 Antigen tests can be run in parallel in small spaces without operating any complex and slow instruments while maintaining test accuracy and reliability.

In the USA, the SPERA™ COVID-19 Antigen Test has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories; use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high, or waived complexity tests. The SPERA™ COVID-19 Ag Test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.